• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email
    SC 13G 1 fintarsus.htm 13G HTML File DOCUMENT TYPE SC 13G
    TEXT


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


    Name of Issuer: TARSUS PHARMACEUTICALS INC
    _____________________________________________________
    Title of Class
    of Securities: Common Stock

    CUSIP Number: 87650L103

    1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON

    Prudential Financial, Inc. 22-3703799

    2.) MEMBER OF A GROUP: (a) N/A
    (b) N/A

    3) SEC USE ONLY:



    4) PLACE OF ORGANIZATION: New Jersey

    NUMBER OF SHARES BENEFICIALLY OWNED BY REPORTING PERSON WITH:

    5) Sole Voting Power: 46,811 See Exhibit A
    6) Shared Voting Power: 2,248,589 See Exhibit A
    7) Sole Dispositive Power: 46,811 See Exhibit A
    8) Shared Dispositive Power: 2,248,589 See Exhibit A

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED: 2,295,400 See Exhibit A

    10) AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES: Not applicable

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 6.0 See Exhibit A

    12) TYPE OF REPORTING PERSON: HC

    ITEM 1(a). NAME OF ISSUER:

    TARSUS PHARMACEUTICALS INC

    ITEM 1(b). ADDRESS OF ISSUER'S EXECUTIVE OFFICES:

    15440 LAGUNA CANYON ROAD IRVINE, CA 92618

    ITEM 2(a). NAME OF PERSON FILING:

    Prudential Financial, Inc.

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    751 Broad Street
    Newark, New Jersey 07102-3777

    ITEM 2(c). CITIZENSHIP:

    New Jersey

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2(e). CUSIP NUMBER:

    87650L103

    ITEM 3. The Person filing this statement is a Parent Holding Company as
    defined in Section 240.13d-1(b)(1)(ii)(G) of the Securities Exchange
    Act of 1934.

    ITEM 4. OWNERSHIP:

    (a) Number of Shares
    Beneficially Owned: 2,295,400 See Exhibit A


    (b) Percent of Class: 6.0


    (c) Powers                No. Of Shares
    ----------- --------------------
    Sole power to vote or 46,811 See Exhibit A to direct the vote
    Shared power to vote or 2,248,589 See Exhibit A to direct the vote
    Sole power to dispose or 46,811 See Exhibit A to direct disposition
    Shared power to dispose 2,248,589 See Exhibit A or to direct disposition

    ITEM 5. OWNERSHIP OF 5% OR LESS OF A CLASS:

    Not Applicable

    ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF
    ANOTHER PERSON:

    Our clients may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities which are the subject of this filing.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE
    SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
    REPORTED ON BY THE ULTIMATE PARENT COMPANY:

    See Exhibit A

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
    MEMBERS OF THE GROUP:

    Not Applicable

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

    Not Applicable

    ITEM 10. CERTIFICATION:

    By signing below, Prudential Financial, Inc. certifies that, to the best of its
    knowledge and belief, the securities referred to above were acquired
    and are held in the ordinary course of business and were not acquired
    and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction
    having that purpose or effect.


    The filing of this statement should not be construed as an admission that
    Prudential Financial, Inc. is, for purposes of Sections 13 or 16 of the Securities
    Exchange Act of 1934, the beneficial owner of such shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief,
    Prudential Financial, Inc. certifies that the information set forth in this
    statement is true, complete and correct.

    PRUDENTIAL FINANCIAL, INC.

    By:Richard Baker
    Second Vice President

    Date:11-14-2024
    As of:9-30-2024

    Exhibit A
    --------------

    ITEM 4. OWNERSHIP:

      Through its parent/subsidiary relationship, Prudential Financial, Inc. may
      be deemed the beneficial owner of the same securities as the Item 7 listed
      subsidiaries and may have direct or indirect voting and/or investment
      discretion over 2,295,400 shares.
      

    These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Prudential Financial, Inc. is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares.




    ITEM 7. IDENTIFICATION/CLASSIFICATION:

    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names:
    

    
    
    Subsidiaries Number of Shares Percentage
    The Prudential Insurance Company of America IC 13,325 0.0
    Jennison Associates LLC IA 2,178,580 5.7
    PGIM, Inc. IA 101,000 0.3
    PGIM Quantitative Solutions LLC IA 2,495 0.0
    PRUCO Securities, LLC IA 0 0.0





    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    6/2/2025$75.00Outperform
    Oppenheimer
    5/27/2025$72.00Buy
    H.C. Wainwright
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    More analyst ratings

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Farrow Jeffrey S converted options into 27,881 shares and sold $550,035 worth of shares (13,608 units at $40.42), increasing direct ownership by 64% to 36,704 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      6/18/25 4:07:59 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Lin Elizabeth Yeu converted options into 3,350 shares and sold $41,326 worth of shares (1,006 units at $41.08), increasing direct ownership by 44% to 7,694 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      6/17/25 4:07:05 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Chaudhuri Bhaskar converted options into 3,350 shares, increasing direct ownership by 63% to 8,700 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      6/16/25 4:05:31 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care